{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:17:14Z","timestamp":1788437834015,"version":"build-2803163510"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Artificial intelligence-driven drug design (AIDD) is increasingly transforming cancer drug discovery, but its applications are often considered as individual computational tasks rather than interconnected stages of the drug discovery pipeline. This mini-review addresses this gap by firstly identifying the following four interconnected stages of anticancer drug development (1) target identification and biomarker-guided prioritization (2), structure-based and generative molecular design (3), perturbational mechanism-of-action assessment, and (4) drug response, resistance, and combination prioritization. It, secondly, describes how AI can be integrated across these four stages in a design-test-refine workflow where AI-generated predictions are progressively evaluated and refined through experimental and patient-relevant evidence. We emphasize that the role of AI in predicting target dependency, molecular activity, mechanism-of-action, or drug response should be to guide rather than replace experimental discovery or clinical judgment. Key limitations to the application of AIDD in cancer are highlighted, including in training and benchmarking data, in accounting for biological heterogeneity, as well as in model generalization. Importantly, robust validation across increasingly complex cancer models is required and it is proposed that AIDD should be used to prioritize testable treatment predictions. Ultimately, translationally useful AIDD workflows should move beyond isolated predictions toward iterative, biologically informed therapeutic development, to form a holistic design-test-refine workflow.<\/jats:p>","DOI":"10.3389\/fonc.2026.1937655","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:54:21Z","timestamp":1788436461000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating artificial intelligence across the cancer drug discovery pipeline using a design-test-refine workflow"],"prefix":"10.3389","volume":"16","author":[{"given":"Jinming","family":"Bai","sequence":"first","affiliation":[{"name":"Division of Cell Biology, Department of Human Biology, Faculty of Health Sciences, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Sarah","family":"Faure","sequence":"additional","affiliation":[{"name":"Division of Cell Biology, Department of Human Biology, Faculty of Health Sciences, University of Cape Town","place":["Cape Town, South Africa"]},{"name":"Department of Chemistry, Faculty of Science, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawfeeq Ahmed","family":"Khalfe","sequence":"additional","affiliation":[{"name":"Division of Cell Biology, Department of Human Biology, Faculty of Health Sciences, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqin","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery (Ministry of Education), National Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly Ann","family":"Burmeister","sequence":"additional","affiliation":[{"name":"Division of Cell Biology, Department of Human Biology, Faculty of Health Sciences, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"van Niekerk","sequence":"additional","affiliation":[{"name":"Division of Cell Biology, Department of Human Biology, Faculty of Health Sciences, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Prince","sequence":"additional","affiliation":[{"name":"Division of Cell Biology, Department of Human Biology, Faculty of Health Sciences, University of Cape Town","place":["Cape Town, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.106140","article-title":"A comprehensive review on recent approaches for cancer drug discovery associated with artificial intelligence","volume":"150","author":"Pandiyan","year":"2022","journal-title":"Comput Biol Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1609827","article-title":"Artificial intelligence in oncology drug development and management: a precision medicine perspective","volume":"15","author":"Fang","year":"2025","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103992","article-title":"Unleashing the power of generative AI in drug discovery","volume":"29","author":"Gangwal","year":"2024","journal-title":"Drug Discov Today"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fsysb.2023.1126044","article-title":"Application of perturbation gene expression profiles in drug discovery-from mechanism of action to quantitative modelling","volume":"3","author":"Szalai","year":"2023","journal-title":"Front Syst Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1086097","article-title":"Deep learning methods for drug response prediction in cancer: predominant and emerging trends","volume":"10","author":"Partin","year":"2023","journal-title":"Front Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1103-9","article-title":"Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens","volume":"568","author":"Behan","year":"2019","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccell.2023.12.016","article-title":"A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization","volume":"42","author":"Pacini","year":"2024","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh1275","article-title":"Predicting and characterizing a cancer dependency map of tumors with deep learning","volume":"7","author":"Chiu","year":"2021","journal-title":"Sci Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00789-y","article-title":"Building a translational cancer dependency map for The Cancer Genome Atlas","volume":"5","author":"Shi","year":"2024","journal-title":"Nat Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"7748","DOI":"10.1038\/s41467-022-35378-z","article-title":"Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens","volume":"13","author":"Srivatsa","year":"2022","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.07.027","article-title":"Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality","volume":"158","author":"Jerby-Arnon","year":"2014","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1038\/s41467-018-04647-1","article-title":"Harnessing synthetic lethality to predict the response to cancer treatment","volume":"9","author":"Lee","year":"2018","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1109\/JBHI.2021.3079302","article-title":"Prediction of synthetic lethal interactions in human cancers using multi-view graph auto-encoder","volume":"25","author":"Hao","year":"2021","journal-title":"IEEE J BioMed Health Inform"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btab271","article-title":"KG4SL: knowledge graph neural network for synthetic lethality prediction in human cancers","volume":"37","author":"Wang","year":"2021","journal-title":"Bioinformatics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btad261","article-title":"KR4SL: knowledge graph reasoning for explainable prediction of synthetic lethality","volume":"39","author":"Zhang","year":"2023","journal-title":"Bioinformatics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btad764","article-title":"ELISL: early-late integrated synthetic lethality prediction in cancer","volume":"40","author":"Tepeli","year":"2024","journal-title":"Bioinformatics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae425","article-title":"Synthetic lethal connectivity and graph transformer improve synthetic lethality prediction","volume":"25","author":"Fan","year":"2024","journal-title":"Brief Bioinform"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9058","DOI":"10.1038\/s41467-024-52900-7","article-title":"Benchmarking machine learning methods for synthetic lethality prediction in cancer","volume":"15","author":"Feng","year":"2024","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.ccell.2022.06.010","article-title":"Pan-cancer proteomic map of 949 human cell lines","volume":"40","author":"Gon\u00e7alves","year":"2022","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20188250","article-title":"INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases","volume":"15","author":"Beekhof","year":"2019","journal-title":"Mol Syst Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1038\/s41467-025-59779-y","article-title":"Comprehensive evaluation of phosphoproteomic-based kinase activity inference","volume":"16","author":"M\u00fcller-Dott","year":"2025","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1038\/s41467-020-17336-9","article-title":"Proteome activity landscapes of tumor cell lines determine drug responses","volume":"11","author":"Frejno","year":"2020","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/pro.70376","article-title":"Assessing the relation between protein phosphorylation, AlphaFold3 models, and conformational variability","volume":"35","author":"Ramasamy","year":"2026","journal-title":"Protein Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ph19060916","article-title":"AI in drug discovery: clinical failures, regulatory reality, and the validation crisis behind the hype","volume":"19","author":"Khairil","year":"2026","journal-title":"Pharm (Basel)"},{"key":"B28","article-title":"DiffDock: diffusion steps, twists, and turns for molecular docking","author":"Corso","year":"2023"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41467-024-45461-2","article-title":"DynamicBind: predicting ligand-specific protein-ligand complex structure with a deep equivariant generative model","volume":"15","author":"Lu","year":"2024","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2026.2636192","article-title":"Deep generative molecular design and its value in modern drug discovery","volume":"21","author":"Ozdemir","year":"2026","journal-title":"Expert Opin Drug Discov"},{"key":"B31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13321-025-01059-4","article-title":"Generative artificial intelligence based models optimization towards molecule design enhancement","volume":"17","author":"Khater","year":"2025","journal-title":"J Cheminform"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1039\/D3SC04185A","article-title":"PoseBusters: AI-based docking methods fail to generate physically valid poses or generalise to novel sequences","volume":"15","author":"Buttenschoen","year":"2024","journal-title":"Chem Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s42256-025-01160-1","article-title":"Assessing the potential of deep learning for protein-ligand docking","volume":"8","author":"Morehead","year":"2026","journal-title":"Nat Mach Intell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1039\/D2SC05709C","article-title":"AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor","volume":"14","author":"Ren","year":"2023","journal-title":"Chem Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.117662","article-title":"Discovery of 3-hydroxymethyl-azetidine derivatives as potent polymerase theta inhibitors","volume":"103","author":"Wang","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02526-3","article-title":"Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors","volume":"43","author":"Ghazi Vakili","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PloS Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1186\/s12964-024-01954-7","article-title":"Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth","volume":"22","author":"Zhou","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B39","doi-asserted-by":"publisher","first-page":"10759","DOI":"10.1038\/s41467-025-65796-8","article-title":"Discovery of a bifunctional PKMYT1-targeting PROTAC empowered by AI-generation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00174","article-title":"The synthesizability of molecules proposed by generative models","volume":"60","author":"Gao","year":"2020","journal-title":"J Chem Inf Model"},{"key":"B41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10822-024-00552-6","article-title":"The AI-driven drug design (AIDD) platform: an interactive multi-parameter optimization system integrating molecular evolution with physiologically based pharmacokinetic simulations","volume":"38","author":"Jones","year":"2024","journal-title":"J Comput-Aided Mol Des"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1039\/C9SC04503A","article-title":"Scaffold-based molecular design with a graph generative model","volume":"11","author":"Lim","year":"2020","journal-title":"Chem Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation Connectivity Map: L1000 platform and the first 1,000,000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.71880","article-title":"A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer","volume":"11","author":"Yang","year":"2022","journal-title":"Elife"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100492","article-title":"A community challenge for a pancancer drug mechanism of action inference from perturbational profile data","volume":"3","author":"Douglass","year":"2022","journal-title":"Cell Rep Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s42256-020-00285-9","article-title":"A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing","volume":"3","author":"Pham","year":"2021","journal-title":"Nat Mach Intell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2022.100441","article-title":"Chemical-induced gene expression ranking and its application to pancreatic cancer drug repurposing","volume":"3","author":"Pham","year":"2022","journal-title":"Patterns (N Y)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1010367","article-title":"Deep learning prediction of chemical-induced dose-dependent and context-specific multiplex phenotype responses and its application to personalized Alzheimer's disease drug repurposing","volume":"18","author":"Wu","year":"2022","journal-title":"PloS Comput Biol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1038\/s41467-024-49620-3","article-title":"Deep representation learning of chemical-induced transcriptional profile for phenotype-based drug discovery","volume":"15","author":"Tong","year":"2024","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","first-page":"9256","DOI":"10.1038\/s41467-024-53457-1","article-title":"Predicting transcriptional responses to novel chemical perturbations using deep generative model for drug discovery","volume":"15","author":"Qi","year":"2024","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s42256-025-01165-w","article-title":"Modelling drug-induced cellular perturbation responses with a biologically informed dual-branch transformer","volume":"8","author":"Guo","year":"2026","journal-title":"Nat Mach Intell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1038\/s41467-026-69677-6","article-title":"Spatial perturb-seq: single-cell functional genomics within intact tissue architecture","volume":"17","author":"Shen","year":"2026","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.cels.2022.10.001","article-title":"Morphology and gene expression profiling provide complementary information for mapping cell state","volume":"13","author":"Way","year":"2022","journal-title":"Cell Syst"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ccell.2020.09.014","article-title":"Predicting drug response and synergy using a deep learning model of human cancer cells","volume":"38","author":"Kuenzi","year":"2020","journal-title":"Cancer Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00169-2","article-title":"Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients","volume":"2","author":"Ma","year":"2021","journal-title":"Nat Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz318","article-title":"MOLI: multi-omics late integration with deep neural networks for drug response prediction","volume":"35","author":"Sharifi-Noghabi","year":"2019","journal-title":"Bioinformatics"},{"key":"B60","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12859-021-04146-z","article-title":"Super.FELT: supervised feature extraction learning using triplet loss for drug response prediction with multi-omics data","volume":"22","author":"Park","year":"2021","journal-title":"BMC Bioinf"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1038\/s41467-020-19313-8","article-title":"Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients","volume":"11","author":"Kong","year":"2020","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41698-025-01082-6","article-title":"PharmaFormer predicts clinical drug responses through transfer learning guided by patient-derived organoid","volume":"9","author":"Zhou","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.medj.2022.11.001","article-title":"Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome","volume":"4","author":"Dinstag","year":"2023","journal-title":"Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00793-2","article-title":"A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics","volume":"5","author":"Hoang","year":"2024","journal-title":"Nat Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00756-7","article-title":"PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors","volume":"5","author":"Sinha","year":"2024","journal-title":"Nat Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1008653","article-title":"TranSynergy: mechanism-driven interpretable deep neural network for the synergistic prediction and pathway deconvolution of drug combinations","volume":"17","author":"Liu","year":"2021","journal-title":"PloS Comput Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn7824","article-title":"An ex vivo platform to guide drug combination treatment in relapsed\/refractory lymphoma","volume":"14","author":"Goh","year":"2022","journal-title":"Sci Transl Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00780","article-title":"Prospective clinical validation of a combinatorial functional precision medicine platform in relapsed\/refractory non-Hodgkin's lymphoma","volume":"9","author":"Lee","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1038\/s41467-024-52980-5","article-title":"Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones","volume":"15","author":"Ianevski","year":"2024","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-3840","article-title":"A machine learning-based strategy predicts selective and synergistic drug combinations for relapsed acute myeloid leukemia","volume":"85","author":"Chen","year":"2025","journal-title":"Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt1851","article-title":"Machine learning-assisted exploration of multidrug-drug administration regimens for organoid arrays","volume":"11","author":"Yakavets","year":"2025","journal-title":"Sci Adv"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1038\/s41467-026-72903-w","article-title":"Critical evaluation of drug response prediction models with DrEval","volume":"17","author":"Bernett","year":"2026","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.patrec.2025.10.016","article-title":"Drug response prediction: a critical systematic review of current datasets and methods","volume":"199","author":"Tran","year":"2025","journal-title":"Pattern Recognit Lett"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1937655\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:54:22Z","timestamp":1788436462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1937655\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":73,"alternative-id":["10.3389\/fonc.2026.1937655"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1937655","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1937655"}}